Drug formulation specialist MedPharm opens US facility in Research Park Triangle
The new laboratories will enable pharmaceutical companies to test various topical and transdermal formulations for both new and existing drugs.
MedPharm has opened a new US-based subsidiary - MP Pharma Services - to expand its service offering to both US and global clients.
“Our new laboratories enable pharmaceutical companies to test various topical and transdermal formulations such as creams, gels and sprays for both new and existing drugs,” says Professor Marc Brown, Co-founder and CSO: “Over the last 20 years, MedPharm has established an undisputed leadership position in topical and transdermal formulation development. We have built strong relationships with many of the major pharmaceutical players and this major investment will enable us to provide our clients with an even faster response to their development challenges, whether it is for new chemical entities, reformulation, generics or claim substantiation.”
Dr Jon Lenn, VP MedPharm US says: “I am excited to have joined MedPharm with its high level of scientific rigor and new US laboratories in Research Park Triangle, NC. We are looking forward to offering clients a host of innovative biological models and automated systems that will greatly de-risk and expedite their development programs.”
The facility will provide clients with access to MedPharm’s unique and novel in vitro models. These allow assessment of new drug candidate libraries and formulation performance through efficacy, target engagement and delivery testing in quicker and more reliable ways than previously possible.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.